Skip to main content
52°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
607.41
+1.49 (+0.25%)
Streaming Delayed Price
Updated: 2:59 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Argenx Dives On Autoimmune Therapy Failure
December 20, 2023
A treatment for a skin-blistering condition failed to beat a placebo.
Via
Investor's Business Daily
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
December 20, 2023
From
argenx SE
Via
GlobeNewswire
Stifel Maintains Buy Rating for argenx: Here's What You Need To Know
December 18, 2023
Via
Benzinga
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
December 01, 2023
Via
Benzinga
Analyst Ratings for argenx
November 29, 2023
Via
Benzinga
These 2 Stocks Are Falling in a Fading Rally
November 28, 2023
It's been a good month, but the stock market's looking tired.
Via
The Motley Fool
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
November 15, 2023
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
November 01, 2023
Via
Benzinga
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know
November 30, 2023
Via
Benzinga
Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
November 29, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Earnings Outlook For argenx
October 30, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
October 19, 2023
Via
Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
Why Is Dutch Pharma Argenx Trading Lower Today?
November 28, 2023
Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia...
Via
Benzinga
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
November 28, 2023
The company was hoping its drug would make a difference for patients with a rare blood disorder.
Via
Investor's Business Daily
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
November 28, 2023
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 28, 2023
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!
Via
InvestorPlace
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 28, 2023
U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
November 28, 2023
From
argenx SE
Via
GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Via
Benzinga
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
November 16, 2023
From
argenx SE
Via
GlobeNewswire
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
November 06, 2023
Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth.
Via
InvestorPlace
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 01, 2023
From
argenx SE
Via
GlobeNewswire
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
October 31, 2023
The company sells Vyvgart, a treatment for generalized myasthenia gravis.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
October 24, 2023
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.